Efficacy and safety of belumosudil for refractory chronic graft-versus-host disease in routine practice
Abstract Chronic graft versus host disease (cGVHD) affects 30–50% of allogeneic hematopoietic stem cell transplantation recipients, with those failing standard therapy including ruxolitinib constituting an important unmet medical need. We retrospectively analyzed the use of the ROCK2 inhibitor belum...
Сохранить в:
| Главные авторы: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer
2026-02-01
|
| Серии: | Annals of Hematology |
| Предметы: | |
| Online-ссылка: | https://doi.org/10.1007/s00277-026-06760-4 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|